Nabriva Therapeutics Plc Is A Biopharmaceutical Company Focused On Developing And Commercializing Innovative Anti Infective Agents For Serious Infectionsheadquartered In Dublinirelandthe Company Has Operational Locations In The United States And Austriaestablished In 2005Nabriva Aims To Tackle The Global Challenge Of Bacterial Resistance Through Its Experienced Team Of Scientists And Industry Experts The Company Has Developed Key Products Including Xenletathe First Systemic Pleuromutilin Antibiotic For Community Acquired Bacterial Pneumoniaand Contepoan Epoxide Antibiotic For Complicated Urinary Tract Infectionsnabriva Also Promotes Sivextroan Oxazolidinone Class Antibacterialunder An Exclusive Agreement With Merck & Co Inccommitted To Addressing Antibiotic Resistancenabriva Actively Seeks Collaborations And Licensing Opportunities To Advance Its Mission And Expand Its Product Pipeline
